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Background: The net benefit of aspirin in prevention of
CVDandnonvascular events remains unclear.Our objec-
tivewas to assess the impact (and safety) of aspirin onvas-
cular and nonvascular outcomes in primary prevention.
Data Sources: MEDLINE, Cochrane Library of Clini-
cal Trials (up to June 2011) and unpublished trial data
from investigators.
Study Selection: Nine randomized placebo-
controlled trials with at least 1000 participants each, re-
porting on cardiovascular disease (CVD), nonvascular out-
comes, or death were included.
Data Extraction: Three authors abstracted data. Study-
specific odds ratios (ORs) were combined using random-
effectsmeta-analysis.Risksvsbenefitswereevaluatedbycom-
paring CVD risk reductions with increases in bleeding.
Results:During amean (SD) follow-up of 6.0 (2.1) years
involving over 100 000 participants, aspirin treatment re-
duced total CVD events by 10% (OR, 0.90; 95% CI, 0.85-
0.96; number needed to treat, 120), driven primarily by
reductioninnonfatalMI(OR,0.80;95%CI,0.67-0.96;num-
ber needed to treat, 162). There was no significant reduc-
tion in CVD death (OR, 0.99; 95% CI, 0.85-1.15) or can-
cermortality (OR,0.93; 95%CI, 0.84-1.03), and therewas
increased riskofnontrivial bleedingevents (OR,1.31;95%
CI, 1.14-1.50; number needed to harm, 73). Significant
heterogeneitywasobserved for coronaryheartdisease and
bleeding outcomes, which could not be accounted for by
major demographic or participant characteristics.
Conclusions: Despite important reductions in nonfatal
MI, aspirin prophylaxis in peoplewithout prior CVDdoes
not lead to reductions in either cardiovascular deathor can-
cermortality. Because thebenefits are further offset by clini-
cally important bleeding events, routine use of aspirin for
primary prevention is not warranted and treatment deci-
sions need to be considered on a case-by-case basis.
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W HILE META-ANALY-ses to date1,2 haveshownmodest ben-efits of aspirin forthe primary preven-
tion of cardiovascular disease (CVD), it re-
mains unclear to what extent these ben-
efits are offset by clinically important
bleeding episodes. Emerging data frompri-
mary and secondary prevention trials also
suggest significant reductions in cancer
mortality in people receiving aspirin pro-
phylaxis,3 stimulating discussions for
more widespread use of this agent
among healthy individuals.4 Current
guidelines for use of aspirin in primary
prevention of CVD are based on informa-
tion from trials published up to 2005,5,6
since when at least 3 additional studies
have been reported.7-9 In this meta-analy-
sis we therefore aimed to provide an up-
dated synthesis of evidence regarding the
wider role of aspirin in primary preven-
tion, including its effect on hitherto un-
derinvestigated outcomes such as non-
vascular disorders (especially cancer),
and to assess whether the risks vs ben-
efits of aspirin treatment vary impor-
tantly according to key demographic or
participant characteristics.10-12
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METHODS
We searched the electronic databases
PubMedandCochraneLibrary from their
inception to June 2011 using terms re-
lated to aspirin, coronary heart disease
(CHD),CVD, cancer, nonvascular events,
all-causemortality, clinical trials, andpri-
mary prevention, without restriction to
anylanguage(Figure1).Thiswassupple-
mentedbyhand-searchingtheir reference
lists foradditionalstudies.Ourpredefined
inclusion criteria were randomized
placebo-controlledtrialsthathadincluded
at least 1000participants (withoutprevi-
ousCHDorstroke, ie,primaryprevention
studies) andhad at least 1 year of follow-
up during which CHD and/or CVD out-
comes(CHD,stroke,cerebrovasculardis-
ease,heart failure, andperipheral arterial
disease[PAD])wererecordedas themain
end points, and details were provided of
bleeding events. As data on cancer and
othernonvascularoutcomesweregener-
ally unavailable in primary trial reports,
we obtained relevant information from
(1) subsequent trial reports thathadpub-
lishedinformationonnonvascularevents13;
(2) a recent individual-participant data
meta-analysis of aspirin in mixed popu-
lations3 (ie, including both primary and
secondary prevention populations) and
usingnumbersprovidedtherein toderive
dataonadditionalendpoints likenoncan-
cer, nonvascular death; (3) investigators
of individualstudies(2studies[Hyperten-
sionOptimalTreatmentTrial{HOT}14and
Physicians’HealthStudy{PHS}15]provided
previously unpublisheddata on cancer).
Asnonvascularoutcomesweregenerally
reportedasfatalevents,riskestimateswere
calculated for cancer and other nonvas-
cularmortalityratherthanincidence.Trials
that enrolled subjects with pre-existing
PADwereeligible for inclusionif theyhad
beenasymptomatic for thisconditionand
had no history of CVD. Trials of second-
arypreventionormixedprimaryandsec-
ondary prevention,16 pilot studies,17 and
studies comparing aspirinwithother an-
tiplatelet agents insteadofplacebo18were
excluded. Incaseofmultiplepublications
from the same source, we used informa-
tion from the primary trial report unless
statedotherwise.Thus, 9 trials involving
102 621participantswere eligible for the
meta-analysis.
Three authors (S.W., R.S., and S.N.)
independentlyabstractedthedata(includ-
ingdemographiccharacteristics,number
of participants and events,mean [orme-
dian] follow-up duration, and risk esti-
mates), anddiscrepancieswere resolved
throughdiscussion(S.R.K.S.andK.K.R.).
For studies that reportedcombinedclini-
cal end points and at least 1 subsidiary
endpoint (eg, totalCHDandeithernon-
fatal MI or fatal CHD but not both), the
numberofeventsforthemissingendpoint
werecalculatedbysimplesubtraction(or
addition,asrelevant),assumingthat these
events did not overlap. Our primary ef-
ficacyendpointsweretotalCHDandtotal
cancermortality,with the secondary ef-
ficacy end points being subtypes of vas-
cular disease, total CVD events, cause-
specific death, and all-cause mortality.
Because definitions for major bleeding
events varied across studies, and since
participant-leveldatawereunavailable to
allow reclassification according to stan-
dardcriteria,19,20wedefinedacategoryof
clinically “nontrivial” bleeding (fatal
bleeding from any site; cerebrovascular
or retinalbleeding;bleeding fromhollow
viscus;bleedingrequiringhospitalization
and/or transfusion;or study-definedma-
jor bleeding regardless of source) as our
compositeprimary safetyendpoint.This
roughly corresponds to type 2 or above
of theBleedingAcademicResearchCon-
sortium definition for bleeding.21
Detailed search of Cochrane and MEDLINE using terms Aspirin AND 
Primary Prevention AND Cardiovascular Disease AND Mortality OR 
Aspirin AND Primary Prevention AND Cancer
Potentially relevant articles (610 from MEDLINE and 70 from
the Cochrane Library)
680
Articles were excluded because they were reviews
or not clinical trials
445
Citations were excluded because they overlapped
between databases
14
Citations tested interventions other than aspirin
and therefore were excluded
44
Citations were excluded because they were not
placebo-controlled trials
11
Citations were excluded because they ascertained
outcomes not relevant to this meta-analysis
8
Citations were excluded because they were not
primary prevention trials
77
Studies were excluded because they were not
randomized controlled trials
17
Studies were identified and included through hand-
searching reference lists of other citations
2
Citations were related to relevant primary prevention
trials testing aspirin and cardiovascular outcomes or
cancer outcomes
66
Original publications were related to aspirin in
primary prevention of cardiovascular disease
12
Original trials were included in our meta-analysis:
PHS,23 BDS,22 HOT,24 PPP,26 TPT,25 WHS,13 
POPADAD,7 JPAD,8 and AAA9
9
Citations were follow-up publications related to
original trials and therefore were excluded
54
ASPREE was ongoing study and was therefore excluded;
PACE and LASAF were excluded because they did not 
fulfill inclusion criteria
Figure 1. Details of literature review. See Abbreviations footnote in the Table for a list of the trial names.
ASPREE indicates Aspirin in Reducing Events in the Elderly; LASAF, Low-Dose Aspirin, Stroke, Atrial
Fibrillation; and PACE, Prevention With Low-Dose Aspirin of Cardiovascular Disease in the Elderly.
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To assess the effect of aspirinwe cal-
culated study-specific unadjusted odds
ratios(ORs)beforecombiningthemusing
random-effectsmeta-analysis(fixed-effect
meta-analyseswere conducted for com-
parison).WeusedcalculatedORs instead
of reportedhazard ratios (HRs) tomaxi-
mize available data on individual end
points,andforconsistency.Giventherare
occurrenceofmanyoutcomes inprimary
prevention, we assumed that the calcu-
latedORswouldclosely approximate re-
ported HRs. Because individual studies
differedwith regard tovariouscharacter-
istics,heterogeneitywasquantifiedusing
the I2 statistic,22 andpotential sources of
heterogeneitywereexploredbysubgroup
analyses andmetaregression. The I2 sta-
tisticmeasures the proportionof overall
variation in effect estimates that is attrib-
utable to between-study heterogeneity.
Subgroup analyses involved grouping
studies according to predefined charac-
teristics andcalculating stratum-specific
ORsusing random-effectsmeta-analysis.
As analyses involved aggregate (andnot
individual-participant) data, it was not
possible to study effect-modification by
variousparticipant-level characteristics.
Metaregression was used instead to ex-
plore heterogeneity, using trial-level in-
formation. Crude event rates for aspirin
andcontrolgroupswerecalculatedusing
data on number of events and mean
follow-uptime(whenmeanfollow-upwas
unavailable, median duration was used
instead).Tocontextualizenetbenefitdue
to aspirin treatment, we compared rates
ofanystatisticallymeaningfulassociations
(CVDornonfatalMI)with ratesofbleed-
ing.Meanbaselineeventratesforthecom-
bined study population were estimated
by pooling study-specific control event
rates for each outcome using random-
effects meta-analysis. Numbers needed
to treat (NNT)andharm(NNH)werede-
rivedbyapplyingpooledORstothemean
baseline event rates for the combined
study population. Values of NNT and
NNHprovidedhereinrepresent thenum-
berofpersons thatneedtobe treatedwith
aspirin for 6 years (the overall mean
follow-up time in this study) to avert or
incur, respectively, 1 event. Quality of
studieswasevaluatedusingaDelphiscor-
ing system,23 which is based on the fol-
lowing: adequacy of randomization; al-
location concealment; balance between
randomized groups at baseline; a priori
identificationof inclusion criteria; pres-
ence or absence of blinding; use of
intention-to-treat analyses; and report-
ing of point estimates and measures of
variability formain outcomes. Potential
publication bias was investigated using
funnel plots and theEgger test. AllP val-
ues reportedare2-sided;P .05wascon-
sidered statistically significant. Statisti-
cal analyseswere performed using Stata
(version 10.1) software (StataCorp).
RESULTS
STUDY POPULATION
Nine good-quality randomized con-
trolled trials of aspirin for primary
preventionofCVDincluding102621
participants were eligible (Figure 1;
Table ; and eTable 1 [http:/ /
www.archinternmed.com]).7-9,14,15,24-27
Most studies were conducted in
Western populations and tended to
include occupational groups (mainly
health professionals15,24,27). Pooled
weighted mean (SD) age at baseline
for all participants combinedwas 57
(4) years, and 46% (n=47 070)were
male. Although most trials selected
participants at increased risk forCVD,
they did not generally preselect in-
dividuals on the basis of diabetes (ex-
cept Prevention of Progression of Ar-
terial Disease And Diabetes Study
[POPADAD]7 and Japanese Primary
Prevention of Atherosclerosis With
Aspirin for Diabetes Trial [JPAD]8).
Other characteristics, including risk
factors forCVD, variedwidely across
studies.
FOLLOW-UP AND EVENTS
Over a mean (SD) follow-up of 6.0
(2.1) years (approximately 700 000
person-years at-risk) in 9 studies,
2169 CHD events were accrued, of
which 1540 were nonfatal MI and
592 were fatal CHD events. One
study8 did not register any fatal MI
events in the aspirin group; hence,
0.5 events were added to both treat-
ment groups to calculateORs.Other
major outcomes included stroke
(n = 1504); total CVD events
(n=4278); CVD death (n=1285);
nonvascular death (n=2587); can-
cer death (n=1512, 8 studies); non-
cancer, nonvascular death (n=983,
8 studies); all-cause mortality
(n=3895); total bleeding events
(n=40 712); and nontrivial bleed-
ing events (n=10 049). Pooled event
rates per 1000 person-years of fol-
low-up in people randomized to as-
pirin vs placebo were 4.1 vs 5.1 for
nonfatal MI; 1.9 vs 1.9 for fatal MI;
7.0 vs 8.1 for total CHD; 3.8 vs 4.0
for stroke; 12.8 vs 14.1 for total CVD
events; 3.9 vs 4.0 for CVD mortal-
ity; 6.6 vs 7.2 for non-CVD death;
5.3 vs 5.9 for cancer death; 3.1 vs 3.2
for noncancer, nonvascular death;
11.0 vs 11.7 for all-cause mortality;
36.0 vs 21.2 for total bleeding events;
and 9.7 vs 7.4 for nontrivial bleed-
ing events. Losses to follow-up in in-
dividual studies are summarized in
eTable 2.
EFFECTS OF ASPIRIN
ON VASCULAR AND
NONVASCULAR OUTCOMES
Aspirintreatmentwasassociatedwith
a significant 10% reduction in risk of
total CVD events (OR, 0.90; 95%CI,
0.85-0.96), largelyowing toa20%re-
duction in risk of nonfatal MI (OR,
0.80;95%CI,0.67-0.96) (Figure2).
There was no beneficial effect on fa-
talMI (OR,1.06;95%CI,0.83-1.37),
stroke(OR,0.94;95%CI,0.84-1.06),
orCVDdeath(OR,0.99;95%CI,0.85-
1.15).Modest,butnonsignificant, re-
ductionswereobservedfor totalCHD
(OR, 0.86; 95% CI, 0.74-1.01), total
nonvascularmortality(OR,0.92;95%
CI, 0.85-1.00), and all-causemortal-
ity (OR, 0.94; 95%CI, 0.88-1.00), al-
though there was no convincing evi-
denceofbenefitwithregard tocancer
mortality (OR, 0.93; 95% CI, 0.84-
1.03). By contrast, there was a 70%
excess risk of total bleeding events
(OR, 1.70; 95% CI, 1.17-2.46) and a
higher than 30% excess risk of non-
trivialbleedingevents(OR,1.31;95%
CI,1.14-1.50) inpeople receivingas-
pirin (eTable3containsdetailsofdefi-
nitions for bleeding). Qualitatively
similar findings were observed in
analyses restricted to studies of daily
aspirin use (ie, after excludingWom-
en’s Health Study [WHS]13 and
PHS15), except that the risk of non-
trivial bleeding was even higher in
these studies (OR,1.48; 95%CI, 1.17-
1.86; eFigure1).Considerablehetero-
geneity was observed for theORs for
major efficacy and safety end points
(Figure2andeFigure2),whichcould
not be explained by reported charac-
teristics (Figure3 and eFigures 3-5).
The risk of CVD events in people
treated with aspirin was, however,
lower at an older age (eFigure 6), and
that of nontrivial bleedingwas some-
what higher at a younger age and at
higher systolic blood pressure (eFig-
ure 5). Contrary to previous re-
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ports,28 we did not find any signifi-
cant sexdifferences in treatment effect
for total CVD events (eFigure 7).
Lastly, no significant heterogeneity
between studies was observed for
nonvascular, cancer, and all-cause
mortality (P .10; Figure 2).
SENSITIVITY ANALYSES
The effect of aspirin on nonfatal MI
or total CVD eventswas unrelated to
its average daily dose and was more
pronounced in trials published be-
fore 2000 (compared with more re-
cent studies; Figure3). Findingswere
comparable when studies con-
ducted exclusively in non-Western
populations (JPAD8), or peoplewith
diabetes (JPAD8 and POPADAD7) or
asymptomatic PAD(POPADAD7 and
Aspirin for Asymptomatic Athero-
sclerosis Trial [AAA]9), or health care
professionals (British Doctors Study
[BDS],8 PHS,15 andWHS13) were ex-
cluded (eTable 4). Results were also
similar when fixed-effect meta-
analysiswas used instead of random-
effects models. There was no evi-
dence of publication bias (Egger test
P value .05 for all major out-
comes; eFigure 8).
COMPARATIVE MERITS
OF ASPIRIN
The net benefit due to aspirin treat-
ment (expressed as a difference be-
tween absolute event rates in the pla-
cebo and aspirin treatment arms) for
both nonfatal MI and total CVD
events increasedproportionatelywith
background event rates for these out-
comes, although the benefit ap-
peared to be more modest for CVD
than nonfatal MI (Figure 4). Such
benefitswere offset by increased rates
ofnontrivialbleeding, even though for
nonfatal MI there was a suggestion
that at high baseline event rates there
may be net benefit in favor of aspirin
prophylaxis. The NNT to avoid 1
nonfatal MI event over 6 years was
162 (NNT was 120 to avert 1 CVD
event over the sameperiod). By com-
parison, the NNT for nonvascular
deathwas292 (247 for cancer death),
andat least1nontrivial bleedingevent
was caused for every 73 persons
treated with aspirin for approxi-
mately 6 years.
Table. Characteristics of Individual Trials Contributing to the Current Analysis
Source Location Year
No. of
Participants
Age, Mean
(SD), y Male, % Diabetes, % Smokers, %
SBP,
Mean (SD),
mm Hg
BDS24 England 1988 5139 63.6 100 2 31 135.8
PHS15 US 1989 22 071 53.8 100 2 11 128.5
HOT14 Multiple 1998 18 790 61.5 53 8 16 170
TPT25 UK 1998 5085 57.5 100 NS 41 139
PPP26 Italy 2001 4495 64.4 42 17 15 145.1
WHS13 US 2005 39 876 54.6 0 3 13 127.3
POPADAD7 Scotland 2008 1276 60.3 44 100 31 145
JPAD8 Japan 2008 2539 64.5 55 100 21 135
AAA9 Scotland 2010 3350 61.6 28 3 32 147.5
Total or
Mean (SD)
102 621 57.3a (4.1) 46 8 16 138a (17)
Source
Total
Cholesterol,
Mean (SD),
mmol/Lb
Aspirin Dose,
mg, and
Schedule
Aspirin
Formulation
Concomitant
Treatmentb
All
Participants,
Duration of
Follow-up, yc
Aspirin Arm,
Duration of
Follow-up,
Person-yearsd
Placebo Arm,
Duration of
Follow-up,
Person-yearsd
BDS24 NS 500 or 300 daily Ordinary, soluble or
effervescent (500 mg) or
enteric coated (300 mg)
No 6.0 18 820 9470
PHS15 5.46 325 alternate day Regular (most) No 5.02 54 560 54 356
HOT14 6.1 75 daily NS Yes 3.8 35 716 35 686
TPT25 6.4 75 daily Controlled release Yes 6.4 8105 8071
PPP26 6.1 100 daily Enteric coated Yes 3.6 8014 8168
WHS13 5.2 100 alternate day NS Yes 10.1 201 333 201 414
POPADAD7 5.52 100 daily NS Yes 6.7 4275 4275
JPAD8 5.21 81 or 100 daily NS No 4.37 5515 5580
AAA9 6.2a 100 daily Enteric coated No 8.2 13 735 13 735
Total or Mean (SD) 5.5 (0.5) 6.0 (2.1) 350 073 340 755
Abbreviations: AAA, Aspirin for Asymptomatic Atherosclerosis Trial9; BDS, British Doctors Study24; HOT, Hypertension Optimal Treatment Trial14; JPAD, Japanese
Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial8; NS, not stated; PHS, Physicians’ Health Study15; POPADAD, Prevention of Progression of Arterial
Disease and Diabetes Trial7; PPP, Primary Prevention Project26; SBP, systolic blood pressure; TPT, Thrombosis Prevention Trial25; WHS, Women’s Health Study.13
Conventional unit conversion factor: To convert cholesterol to milligrams per deciliter, divide by 0.0259.
aRepresents weighted mean (SD).
bConcomitant treatments include agents other than anti-platelet drugs (eg, blood pressure-lowering medication), as in factorial trials.
cFollow-up duration shown for POPADAD and JPAD represents median follow-up, not mean. Also, total cholesterol values for POPADAD are median, not mean. Data
on cholesterol measurements at baseline were missing in approximately 0.6% of all participants in the AAA study.
dFollow-up duration shown in person-years according to treatment arm was obtained directly from study reports for BDS and TPT, and was calculated based on
numbers per group multiplied by mean (or median) follow-up time for other studies. In PHS, the reported duration of follow-up differed for various outcomes, and the
numbers shown correspond to those for MI (including nonfatal and fatal MI).
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COMMENT
Thismeta-analysis provides the larg-
est evidence to date regarding the
wider effects of aspirin treatment in
primary prevention and contextu-
alizes the relevance of aspirin pro-
phylaxis by comparing CVD risk
reduction against concomitant el-
evation in risk of bleeding. Unlike
previous studies,3 the findings re-
ported herein do not suggest a
protective role for aspirin against
cancer mortality in people at low-
to-moderate risk for CVD events.
Available data also suggest that the
principal cardiovascular effect of as-
pirin in primary prevention is on
nonfatalMIwith no real benefit with
regard to fatal MI, stroke, or CVD
death. Even these benefits are con-
siderably offset by an elevated risk
of bleeding (NNT for nonfatal MI of
162 vs NNH for nontrivial bleed of
73). Although our data failed to con-
clusively identify subgroups of
participants likely to benefit from as-
pirin treatment, the results never-
theless suggest an increased risk of
nontrivial bleeding in individuals re-
ceiving daily (vs alternate day) as-
pirin treatment, with a particularly
unfavorable risk to benefit ratio for
individuals at lower baseline CVD
risk. Since it may be argued that
events such as MI are potentially
more serious compared with bleed-
ing, both patients and physicians
should carefully consider the rela-
tive merits of daily aspirin treat-
ment in primary prevention.
However, modest, nonsignifi-
cant reductions in nonvascular death
and all-cause mortality were ob-
served, with questionable benefits
0.5 1.0 1.5 2.0 2.5
Odds Ratio
Favors aspirin Favors placebo
Outcome
Nonfatal MI
Fatal MI
Total CHD
Stroke
Total CVD events
CVD mortality
Non-CVD mortality
Cancer mortality
Noncancer, nonvascular mortality
All-cause mortality
Total bleeds
Nontrivial bleeds
No. of
studies
9
9
9
9
9
9
9
8
8
9
9
9
No. of cases/
participants, aspirin
699/52 145
329/52 145
1044/52 145
749/52 145
2107/52 145
674/52 145
1276/52 145
750/49 919
481/49 919
1962/52 145
22 297/50 868
5337/50 868
No. of cases/
participants, placebo
841/50 476
263/50 476
1125/50 476
755/50 476
2171/50 476
611/50 476
1311/50 476
762/48 207
502/48 207
1933/50 476
18 415/49 208
4712/49 208
I2 (95% CI)
62.1% (21.7%-81.6%)
37.4% (0.0%-71.2%)
64.8% (28.1%-82.7%)
14.8% (0.0%-56.9%)
00.0% (0.0%-55.4%)
36.1% (0.0%-70.6%)
00.0% (0.0%-4.2%)
00.0% (0.0%-49.4%)
32.1% (0.0%-69.9%)
00.0% (0.0%-0.0%)
98.0% (97.3%-98.5%)
65.7% (30.3%-83.1%)
Odds ratio (95% CI)
0.80 (0.67-0.96)
1.06 (0.83-1.37)
0.86 (0.74-1.01)
0.94 (0.84-1.06)
0.90 (0.85-0.96)
0.99 (0.85-1.15)
0.92 (0.85-1.00)
0.93 (0.84-1.03)
0.90 (0.76-1.07)
0.94 (0.88-1.00)
1.70 (1.17-2.46)
1.31 (1.14-1.50)
Figure 2. Effect of aspirin on vascular and nonvascular outcomes or death. CHD indicates coronary heart disease; CVD, cardiovascular disease; and
MI, myocardial infarction.
Nonfatal MI Total CVD events Nontrivial bleed
Subgroup
Period of publication
After 2000
Before 2000
No. of participants per study
5000 or above
Below 5000
No. of events per study
100 (500) or above
Below 100 (500)
Average daily dose of aspirin
100 mg or above
Less than 100 mg
Schedule of aspirin treatment
Daily
Alternate day
Concomitant treatment
Yes
No
OR (95% CI)
0.98 (0.84-1.14)
0.67 (0.56-0.81)
0.75 (0.58-0.95)
0.93 (0.74-1.17)
0.79 (0.65-0.96)
0.91 (0.48-1.73)
0.81 (0.63-1.03)
0.80 (0.58-1.10)
0.80 (0.66-0.96)
0.78 (0.47-1.31)
0.78 (0.61-1.00)
0.83 (0.60-1.15)
P value
<.001
.11
.65
.51
.80
.39
P value
.66
.73
.43
.96
.38
.88
P value
.004
.06
.002
.12
.002
.08
OR (95% CI)
1.33 (0.97-1.83)
1.37 (1.16-1.61)
1.26 (1.07-1.47)
1.43 (1.05-1.93)
1.16 (1.05-1.29)
1.48 (1.17-1.86)
1.26 (0.99-1.61)
1.40 (1.08-1.82)
1.48 (1.17-1.86)
1.16 (1.05-1.29)
1.33 (1.05-1.69)
1.26 (1.14-1.39)
OR (95% CI)
0.92 (0.83-1.01)
0.89 (0.82-0.97)
0.90 (0.84-0.96)
0.91 (0.77-1.07)
0.88 (0.82-0.96)
0.93 (0.84-1.03)
0.91 (0.81-1.03)
0.90 (0.83-0.98)
0.92 (0.85-1.00)
0.87 (0.79-0.97)
0.90 (0.84-0.98)
0.90 (0.79-1.03)
0.5 1.0 1.5 2.0
Odds Ratio
Favors aspirin Favors placebo
0.5 1.0 1.5 2.0
Odds Ratio
Favors aspirin Favors placebo
0.25 0.5 1.0 1.5 2.0
Odds Ratio
Favors aspirin Favors placebo
Figure 3. Effect of aspirin on nonfatal myocardial infarction (MI), total cardiovascular disease (CVD) events, and nontrivial bleeding events according to various
study-level characteristics. For nonfatal MI, the number of events per study were categorized as 100 and above or below 100. For total CVD events and nontrivial
bleeding, the corresponding categories were 500 and above or below 500. P values are shown for the overall test of heterogeneity between subgroups.
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regarding cancer mortality. Al-
though recent evidence suggests that
aspirin reduces mortality from cer-
tain cancers,3,29 this is based on in-
formation from both primary and
secondary prevention studies. As
background event rates for cancers
and other chronic diseases may be
different for participants with pre-
existing CVD, and since concomi-
tant lifestyle or treatment decisions
may alter risks associatedwith these
outcomes, assessments of risk based
on primary prevention trials is likely
to be more informative. It has also
been argued that the frequency of as-
pirin administration is an impor-
tant determinant of cancer out-
comes, withmore sustained benefits
with daily compared with alternate-
day treatment.3 However, we were
unable to confirm these observa-
tions because cancermortality failed
to reach statistical significance even
after excluding studies that had used
alternate-day aspirin treatment
(WHS13 and PHS15) (OR, 0.88; 95%
CI, 0.76-1.01). It is plausible that
daily aspirin use may prompt ear-
lier detection of cancers owing to in-
vestigation for bleeding, with appar-
ent survival benefits (which may
nevertheless be artifactual).
The findings of our analysismerit
careful consideration in light of ex-
isting evidence regarding aspirin use
in primary prevention. For in-
stance, the magnitude of risk reduc-
tion observed for nonfatal MI and
total CVD events is broadly consis-
tent with some previous reports.30 It
has been suggested that the pharma-
cokinetics of aspirin may be differ-
ent amongmen andwomen,31,32 with
consequent sex differences in effi-
cacy. However, our analysis did not
reveal anymaterial differences in as-
pirin treatment effect by sex. Al-
though these findings may be prone
to ecological and other biases, they
are in agreement with large-scale in-
dividual-participant data meta-
analyses that showed lack of any im-
portant interaction by sex30 formajor
CVD outcomes. Our analysis also
showed that aspirin was no better
thanplacebo for reducingnonfatalMI
events in trials published after 2000,
whichmaybe ascribed tobetter treat-
ments forCVDorunderlying risk fac-
tors. This decline suggests that in
contemporary primary prevention
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Figure 4. Comparison of risk vs benefit due to aspirin treatment for primary prevention of cardiovascular
disease. A, Plot of absolute risk difference in relation to background (ie, placebo) event rate for main
outcomes. B, Plot comparing absolute number of nontrivial bleeding events caused vs absolute number
of nonfatal MI events averted. C, Plot comparing absolute number of nontrivial bleeding caused vs
absolute number of total CVD events averted. In each of the panels, data points and associated labels
correspond to individual studies, while straight lines represent fitted values. In panel A, the x-axis
represents the background (ie, placebo) event rate for each of the outcomes of interest (nonfatal MI, total
CVD, and nontrivial bleed), whereas the y-axis shows risk difference for these outcomes (total number of
events averted in case of nonfatal MI and total CVD, as against total number of adverse events caused in
case of nontrivial bleeding). In panels B and C, the x-axis shows the absolute number of events averted
for nonfatal MI or total CVD, respectively, in each study plotted against the absolute number of nontrivial
bleed events caused in the same studies. See Abbreviations footnote in the Table for a list of the trial
names and reference citations.
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settings, aspirin may add little extra
value to other CVD risk reduction
strategies that target lipid levels, blood
pressure, and smoking, especially in
low-risk individuals.
On the other hand, aspirin may
be associated with net harm owing
to increased potential for bleeding.
Current guidelines for primary pre-
vention advocate widespread use of
aspirin in people at increased risk for
CVD.5,33,34 Others have even sug-
gested regular prophylaxis in people
above a certain age, either singly35
or in combination with other
agents.36However, such strategies re-
quire closer scrutiny because aspi-
rin cannot be compared with either
statins or blood pressure–lowering
agents with regard to its effects on
CVD death. Hence, based on our
findings of a marginal benefit on
nonfatal MI, a nonsignificant effect
on cancer death, and a significantly
increased risk of clinically relevant
bleeding, it is perhaps timely to re-
appraise existing guidelines for as-
pirin use in primary prevention.Our
data additionally highlight the need
for more robust evidence in spe-
cific subgroups of participants,37,38
since current guidelines39 are based
on limited evidence in different sub-
groups. Future studies should there-
fore aim to assess the impact of low-
dose, alternate-day aspirin treatment
on both vascular and nonvascular
outcomes, especially in specific sub-
groups of individuals40 and within
diverse populations.41 Also, owing to
the relatively short mean follow-up
duration reported in this meta-
analysis, longer-term studiesmay be
warranted to clarify the precise role
of aspirin in cancer prevention.
Despite obvious advantages, there
are important limitations to our
analyses. First, we were unable to
harmonize outcome definitions
across studies (especially for out-
comeswith high heterogeneity such
as bleeding) and were further un-
able to quantify precisely the effect
of aspirin treatment in clinically rel-
evant subgroups. Nonetheless, we
combined bleeding episodes that
were unlikely to be trivial and con-
ducted subgroup analyses using
available summary information. Sec-
ond, as data on cancer incidence
were generally unavailable frompub-
lished reports, we were only able to
assess the relationship between
aspirin treatment and cancer mor-
tality. Although thismay have some-
what underestimated this associa-
tion, it may have in fact been
beneficial for study validity be-
cause estimates based on mortality,
rather than incidence, are less likely
to be affected by ascertainment bias.
Third, the effect of aspirin on can-
cer mortality could be evaluated
using information from only 8 of 9
studies. Nevertheless, these results
are fairly robust because the major-
ity of primary prevention trials of as-
pirin were included in our analy-
ses. Fourth, as we studied the effect
of aspirin on multiple outcomes,
some of the associationsmay be due
to chance alone.However, as the risk
estimates were largely consistent
with previous reports,30 the scope of
any artifactual associations is likely
to be limited. Lastly, as most stud-
ies were performed in occupational
groups inWestern populations, find-
ings of this meta-analysis may not
be entirely generalizable.
In conclusion, we found rather
modest benefits of aspirin treat-
ment on nonfatal MI and total CVD
events in primary prevention, while
the effect on cancer mortality was
nonsignificant. Because the ben-
efits of aspirin treatment were ac-
companied by a significant in-
crease in risk of bleeding, further
study is needed to identify subsets
of participant having favorable risk
to benefit ratio for aspirin use in pri-
mary prevention and/or involving
more high-risk participants. In the
absence of such information, a re-
appraisal of current guidelines ap-
pears to be warranted, particularly
in countries where a large number
of otherwise healthy adults are pre-
scribed aspirin, since a significant
proportion of them may develop
bleeding complications.42
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